Contents

Search

metyrapone (Metopirone)

Tradename: Metopirone. Indication: - diagnostic aid for hypothalamic-pituitary ACTH function Dosage: - discontinue all corticosteroid therapy prior to & during administration - day 1: control period: collect 24 hour urine to measure 17-hydroxycorticosteroids &/or 17-ketosteroids - day 2: ACTH test: standard cosyntropin stimulation test - days 3 & 4: rest period - day 5: administer metyrapone, preferably with milk or snack children: 15 mg/kg every 4 hours for 6 doses; minimum of 250 mg/dose adults: 750 mg every 4 hours for 6 doses - day 6: measure 24 hour urine steroids for effect Tabs: 250 mg Adverse effects: - not common (1-10%) - fall in arterial blood pressure, increase in pulse rate, dizziness, vertigo, headache, sedation, allergic rash, nausea, abdominal discomfort, bone marrow suppression Mechanism of action: - blocks cortisol synthesis by inhibiting cyt P450 11B (steroid 11-beta-hydroxylase) - compensatory increase in plasma 11-deoxycortisol

Related

adrenocorticotropic hormone; corticotropin; adrenocorticotropin (ACTH) cosyntropin (ACTH, Cortrosyn) stimulation test (delta cortisol test) metyrapone stimulation test

General

endocrine agent

Database Correlations

PUBCHEM correlations

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. Department of Veterans Affairs, VA National Formulary
  3. Wikipedia: Metyrapone http://en.wikipedia.org/wiki/Metyrapone